Home » Topics » BioWorld Science

BioWorld Science
RSS

Novartis enters license option agreement with Voyager for AAV capsids for gene therapy programs

March 8, 2022

Study finds variants that increase risk of severe COVID-19

March 8, 2022

METTL3 inhibition with STM-2457 leads to antitumor effects in OSCC

March 8, 2022

LABP-73 demonstrates efficacy in preclinical models of chronic asthma

March 8, 2022

BMAL1 disruption has an impact on metabolic and liver disease

March 8, 2022

Nanoengineered Bifidobacterium bifidum suppresses tumors in vivo

March 8, 2022

VYN-201 reduces key inflammatory biomarkers involved in vitiligo pathogenesis in preclinical model

March 7, 2022

Modulation of RICTOR/mTORC2 axis is an approach for sensorineural hearing loss

March 7, 2022

Regulation of BIN1 ameliorates dynamin-related myopathy

March 7, 2022

Novel UV-mediated antigen-presenting nanoparticles for mRNA delivery to virus-specific T cells

March 7, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...